Published in PLoS One on September 17, 2013
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J Virol (2015) 0.86
Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proc Natl Acad Sci U S A (2015) 0.84
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. J Virol (2015) 0.83
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol (2016) 0.78
Distinct roles of vaccinia virus NF-kB inhibitor proteins A52, B15 and K7 in the immune response. J Virol (2017) 0.75
A prime/boost PfCS14K(M)/MVA-sPfCS(M) vaccination protocol generates robust CD8(+) T cell and antibody responses to Plasmodium falciparum circumsporozoite protein and protects mice against malaria. Clin Vaccine Immunol (2017) 0.75
Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS One (2016) 0.75
Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine (2016) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 12.00
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A (2011) 5.78
Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature (2000) 4.36
Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol (2008) 4.16
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A (2000) 3.69
Structures of the toll-like receptor family and its ligand complexes. Immunity (2008) 3.36
Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol (2009) 3.17
MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2002) 3.10
The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med (2003) 2.85
Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol (2005) 2.80
Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med (2005) 2.66
Pathogen recognition in the innate immune response. Biochem J (2009) 2.64
Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J (2008) 2.53
Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood (2006) 2.35
Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol (2011) 2.35
Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol (2007) 2.24
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem (2004) 2.21
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem (2008) 1.89
Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci U S A (2006) 1.88
The role of Toll-like receptors in the host response to viruses. Mol Immunol (2005) 1.86
Pattern recognition receptors and the innate immune response to viral infection. Viruses (2011) 1.82
Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J Biol Chem (2003) 1.81
Isolation of mouse peritoneal cavity cells. J Vis Exp (2010) 1.79
Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biol Chem (2005) 1.75
A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS One (2007) 1.73
MyD88 as a bottle neck in Toll/IL-1 signaling. Curr Top Microbiol Immunol (2002) 1.71
The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol (2010) 1.70
A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood (2008) 1.69
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol (2006) 1.66
Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci U S A (2009) 1.65
Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog (2008) 1.63
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem (2004) 1.50
What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol (2011) 1.45
Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci U S A (2011) 1.38
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol (2007) 1.34
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One (2008) 1.23
Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog (2011) 1.22
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol (2010) 1.12
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses (2007) 1.07
Structural insights into TIR domain specificity of the bridging adaptor Mal in TLR4 signaling. PLoS One (2012) 1.05
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection. PLoS Pathog (2008) 1.02
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions. J Biol Chem (2012) 0.99
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One (2009) 0.90
Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses (1992) 0.87
Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87
High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One (2012) 0.85
Poxvirus A46 protein binds to TIR domain-containing Mal/TIRAP via an α-helical sub-domain. Mol Immunol (2011) 0.83
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 5.85
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology (2012) 3.63
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis (2004) 3.25
1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis (2008) 3.19
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 3.04
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77
Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood (2010) 2.69
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med (2012) 2.46
Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Sepsis: time to reconsider the concept. Crit Care Med (2008) 2.17
What's new in antimicrobial use and resistance in critically ill patients? Intensive Care Med (2013) 2.11
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis (2012) 2.11
Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect (2002) 2.10
Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol (2005) 2.09
Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med (2008) 2.05
Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol (2004) 2.05
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A (2009) 2.04
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol (2010) 2.02
Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol (2003) 1.97
β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med (2013) 1.95
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev (2006) 1.94
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88
Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia: a prospective observational study. Clin Infect Dis (2012) 1.83
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta (2002) 1.81
Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med (2005) 1.77
The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol (2007) 1.73
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol (2008) 1.70
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum (2005) 1.66
IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol (2009) 1.65
Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol (2004) 1.65
Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA (2009) 1.63
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 1.62
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57
Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog (2008) 1.57
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immunol (2011) 1.54
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53
Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal (2005) 1.53
ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog (2013) 1.51
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A (2010) 1.50
Sepsis studies need new direction. Lancet Infect Dis (2012) 1.50
Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care (2008) 1.49
Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocr Relat Cancer (2013) 1.49
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood (2002) 1.45
The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med (2003) 1.44
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol (2004) 1.40
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS (2007) 1.39
Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem (2007) 1.39
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ (2003) 1.37
Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis (2005) 1.36
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol (2002) 1.34
Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis (2007) 1.34
Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BMC Infect Dis (2006) 1.31
Large T antigen on the simian virus 40 origin of replication: a 3D snapshot prior to DNA replication. EMBO J (2003) 1.30
Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem J (2005) 1.28
HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis (2007) 1.27
Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol (2013) 1.27